JoVE Logo

Zaloguj się

Aby wyświetlić tę treść, wymagana jest subskrypcja JoVE. Zaloguj się lub rozpocznij bezpłatny okres próbny.

W tym Artykule

  • Podsumowanie
  • Streszczenie
  • Wprowadzenie
  • Protokół
  • Wyniki
  • Dyskusje
  • Ujawnienia
  • Podziękowania
  • Materiały
  • Odniesienia
  • Przedruki i uprawnienia

Podsumowanie

This protocol aims at establishing ubiquitin (Ub) and ubiquitin-likes (Ubls) specific proteomes in order to identify alterations of these kind of post-translational modifications (PTMs), associated with a specific condition such as a treatment or a phenotype.

Streszczenie

Ubiquitin (ub) and ubiquitin-like (ubl) dependent post-translational modifications of proteins play fundamental biological regulatory roles within the cell by controlling protein stability, activity, interactions, and intracellular localization. They enable the cell to respond to signals and to adapt to changes in its environment. Alterations within these mechanisms can lead to severe pathological situations such as neurodegenerative diseases and cancers. The aim of the technique described here is to establish ub/ubls dependent PTMs profiles, rapidly and accurately, from cultured cell lines. The comparison of different profiles obtained from different conditions allows the identification of specific alterations, such as those induced by a treatment for example. Lentiviral mediated cell transduction is performed to create stable cell lines expressing a two-tags (6His and Flag) version of the modifier (ubiquitin or a ubl such as SUMO1 or Nedd8). These tags permit the purification of ubiquitin and therefore of ubiquitinated proteins from the cells. This is done through a two-step purification process: The first one is performed in denaturing conditions using the 6His tag, and the second one in native conditions using the Flag tag. This leads to a highly specific and pure isolation of modified proteins which are subsequently identified and semi-quantified by liquid chromatography followed by tandem mass spectrometry (LC-MS/MS) technology. Easy informatics analysis of MS data using Excel software enables the establishment of PTM profiles by eliminating background signals. These profiles are compared between each condition in order to identify specific alterations which will then be studied more specifically, starting with their validation by standard biochemistry techniques.

Wprowadzenie

The method proposed here is dedicated to study PTMs mediated by the ubiquitin family members from cultured mammalian cells in order to identify potential alterations associated with a specific condition (treatment, differentiation, etc). PTMs represent the last step of regulation of proteins' functions1. Indeed, once produced by the translational machinery, most if not all proteins undergo different kinds of PTMs that modulate their activity, molecular interactions, and intracellular location1. Among the plethora of PTMs are the ones mediated by the ubiquitin family of proteins, ubiquitin itself and all ubiquitin-likes, have the potential to regulate all intracellular or partially cytoplasmic proteins2. Because they are themselves proteins, they can be conjugated to each other, forming homogeneous and heterogeneous chains of diverse topologies, each associated with specific regulatory functions2. Tools are needed to try to decipher and understand this complex machinery. Many approaches were developed worldwide, having their own advantages and disadvantages, and here we propose one with high performance suitable for cultured cells.

The main advantage of this method is its accuracy. Indeed, the purity of isolated modified proteins is highly improved by the combinatorial use of the two tags (6His and Flag) and the two step-procedure and therefore it is much more selective than a single tag fusion Ub/Ubl3,4. The presence of the 6His tag enables a first step of purification in a fully denaturing condition thereby avoiding any co-purification of proteins containing ubiquitin binding domains or other proteins binding to the ubiquitinated ones. This is a technical problem encountered by several other approaches based on affinity purification of ubiquitinated proteomes using either specific antibodies5 or tandem ubiquitin binding elements (TUBEs)6. Importantly, this technique is not biased in favor of purification of a certain type of ubiquitination, as it could be the case for some other approaches, since both mono and different kinds of polyubiquitinations were identified7. Consequently, once found, an alteration of ubiquitination will have to be studied in more details by standard biochemical approaches in order to identify the exact kind of ubiquitination involved.

Finally, another technical advantage of this protocol is the use of lentiviruses, that easily and rapidly creates stable expressing cell lines with reasonable level of expressions of tagged modifier without interfering with the normal cellular behavior.

Whereas one important role of ubiquitination is to target proteins for proteasomal degradation, it is now known that it has many other regulatory properties for potentially most intracellular or partially intracellular proteins1. The number of these functions is further augmented by the existence of many ubiquitin like proteins, forming a family of proteins regulating almost every cell mechanisms1. Their alterations can have drastic impact on the cell biology and can lead or participate in pathological situations8, such as cancer9. Hence, tools are needed to explore this vast landscape and identify the alterations associated with a pathological condition that could serve as novel therapeutic targets.

This protocol is dedicated to cells in culture since they need to be transduced to express exogenous tagged Ub/Ubl. Once created, these stable cell lines can be used to generate Ubl profiles from culture in 2D or 3D or xenografts, thereby extending the horizon of the different experimental models that can be applied to study PTMs profiles.

Protokół

1. Generation of stable cell lines expressing 6His-Flag-Ubl

NOTE: Co-transfection of HEK-293T cells with pCCL-6HF-Ubl, pVSVG and delta-Helper.

  1. Day 0: Seed 293T cells in a 6-well plate to obtain 50-70% confluence the day after.
  2. Day 1: Co-transfect 50-70% confluent cells with a mix of 1 µg of pCCL-6HF-Ubl or pCCL-GFP, 1 µg of pVSVG and 1 µg of delta-Helper vectors, using a transfection reagent and protocol for lentivirus production. After 6 h of transfection, change the medium to a fresh one corresponding to cells to be transduced. Seed the cells to be transduced in a 6 well plate in order to obtain a 10-20% confluence the day after (the day of starting the transduction).
  3. Day 2: 24 h after transfection, recover the medium containing lentiviral particles and filter using 0.45 µm filters. If needed, add fresh medium at this point in order to produce a second batch of lentiviruses. Replace the medium of cells to be transduced (10-20% confluence) by the one containing lentiviruses.
    NOTE: Lentiviral medium can be kept at +4 °C for several days before transduction or stored at -80 °C for months.
  4. Incubate the cells with lentiviruses between 24 h to 72 h in a standard incubator (37 °C, 5% CO2), and then change the medium for fresh standard one. If possible, check GFP expression using an inverted fluorescent microscope to evaluate efficiency of transduction: percentage of expressing cells and relative level of expression per cell. If no fluorescence is detected, wait for additional 2-3 days as expression may take longer depending on cells type to be transduced.
  5. If GFP control is positive, grow all cells until having enough to perform an expression control of 6HF-Ubl by immunofluorescence and Western blot using anti-Flag antibody.

2. Double purification of modified proteins

NOTE: Buffer 1: 6 M Guanidinium-HCl, 0.1 M Na2HPO4/NaH2PO4, pH 8.0, 0.5% Triton X-100.
Buffer 2: 50 mM NaH2PO4, 150 mM NaCl, 1% Tween20, 5% Glycerol, pH 8.0.
Buffer 3: 100 mM NH4HCO3, pH 8.0.

  1. Cell lysis: Once ready, wash culture dishes at least one time with phosphate-buffered saline (PBS) at room temperature (RT) and proceed to cell lysis or, alternatively, flash freeze in liquid N2 and store at -80 °C. For lysis, add 2 mL of Buffer 1 per a 15 cm dish at RT. Use a cell scraper to recover all lysates in 50 mL conical centrifuge tubes (final volume about 20 mL).
  2. Sonicate the lysates three times for 30 s separated by a 1 min pause.
  3. Centrifuge the sonicated lysates at 15,000 x g for 15 min.
  4. Transfer the supernatant to a new tube using a cell strainer (40 µm).
  5. Determine samples' concentration and adjust, if necessary, to obtain the same amount of proteins and same volume. Use a total amount of protein between 50 and 100 mg (10 dishes with 15 cm diameter for MiaPaCa-2 cells).
  6. Add Ni2+-NTA beads, using 2 µL of beads per 1 mg of protein.
  7. Rotate at 30 rpm during 2.5 h at RT.
  8. Pellet the beads at 500 x g for 5 min.
  9. Wash the beads with 1 mL of Buffer 1, transferring the samples to a 1.5 mL microcentrifuge tube, then transfer the tubes on ice. Perform all the next steps on ice or at 4 °C.
  10. Wash two times with 1 mL of ice-cold Buffer 2 containing 10 mM imidazole.
  11. To elute bound proteins, add 600 µL of Buffer 2 containing 250 mM imidazole and rotate for 2 h at 4 °C.
  12. Pellet the beads by centrifugation at 500 x g for 1 min. Transfer the supernatants to new, pre-cooled, 1.5 mL tubes and add 50 µL of anti-Flag M2 antibody conjugated beads.
  13. Rotate at 30 rpm for 2.5 h at 4 °C, then wash 2 times with 500 µL of Buffer 2, then 2 times with 500 µL of Buffer 3.
  14. For the final elution, add 100 µL of Buffer 3 containing a Flag peptide at 0.1 µg/µL and rotate at 4 °C for 1.5 h.
  15. Centrifuge at 500 x g for 1 min and transfer the supernatants to new pre-cooled tubes.
  16. Take 10% (10 µL) to load on SDS-PAGE and perform a silver staining of the gel to control the purification quality. If the purification looks good, analyze the 90% left by LC-MS/MS.

3. Processing of mass spectrometry data to generate profiles of Ub/Ubls PTMs and to identify significant differences between them

NOTE: Results from MS analysis contain many information including the total number of peptides as well as the peak area values (mean of TOP 3 peptide area10) for each protein identified in each samples. These data can be processed using either the peptide count numbers or the peak area values, or both. For calculation with peak areas, because these values are usually in the range of 106, it is necessary to divide them by this order before applying the same formulas as below. The results obtained with both methodologies of counting should show a strong correlation as it usually does. For each identified protein, use the following formulas where:
v1 figure-protocol-5450 peptides values in non-treated ubiquitin sample (e.g., Ub - drug)
v2 figure-protocol-5576 peptides values in Gemcitabine treated ubiquitin sample (e.g., Ub + drug)
k1 figure-protocol-5710 peptides values in non-treated control GFP sample (e.g., GFP - drug)
k2 figure-protocol-5839 peptides values in Gemcitabine treated control GFP sample (e.g., GFP + drug).

  1. Normalization: Normalize values between drug treated cells and untreated cells for Ubiquitin and GFP using the following formulas. Normalized v = V and normalized k = K.
    V1=v1.(∑v1+ ∑v2) / (2. ∑v1) ; V2=v2.(∑v1+ ∑v2) / (2. ∑v2)
    K1=k1.(∑k1+ ∑k2) / (2. ∑k1) ; K2=k2.(∑k1+ ∑k2) / (2. ∑k2)
  2. Removal of background: Using the following formulas, subtract values in control sample (GFP) from values in the ubiquitin sample to obtain specific values (V'1 and V'2) for each identified protein in both conditions.
    V'1=V1-K1 if V1-K1≥0 ; V'1=0 if V1-K1<0
    V'2=V2-K2 if V2-K2≥0 ; V'2 =0 if V2-K2<0
  3. Variation (Var) of ubiquitination. To obtain a score (between -100 and +100) for positive and negative variations of PTMs induced by a drug, use the following formula in which the difference between specific values of treated and untreated samples are divided by the sum of all values, including those in control (to penalize proteins also identified in control GFP), and multiply by 100.
    Var = (V'2-V'1)/(V1+K1+V2+K2)*100 ; -100<Var<100 ;
    Variations below -50 (repression of PTM) or above 50 (induction of PTM) are usually considered as significant.
  4. Confidence (Conf). Use the following formula to obtain a confidence value between 0 and 100%,:
    Conf = ((V1+V2)2/(1+V1+V2+K1+K2)2)*100 - 100/(1+V'1+V'2) ; =0 if <0
    Values above 50 are usually considered to be confident.
  5. To obtain a nicer distribution of induction/repression values and to consider both variation and confidence parameters, multiply Var and Conf values using the following formula where V figure-protocol-7783 Var and C figure-protocol-7844 Conf
    =SI(V2>0;((V2*C2)^2)/(10^6);-((V2*C2)^2)/(10^6))
    NOTE: As peak area values are usually more accurate than peptide counting, it is possible to use specific software which are dedicated to the interpretation of this kind of data such as Perseus (https://www.biochem.mpg.de/5111810/perseus), following recommendations of use.

Wyniki

Transduction of culture mammalian cells to create GFP and 6HF-Ub expressing cells
To produce lentiviruses which will be used later to transduce MiaPaCa-2 cells, 70% confluent HEK-293T cells are co-transfected with an equal amount of the three vectors, pCCL-6HF-Ubiquitin or GFP/Delta-Helper/pvSvG. After 24 h of production, the medium containing lentiviral particles is recovered and filtered. It is possible at this point to control the efficiency of the transfection b...

Dyskusje

We have developed a robust and reliable methodology to generate profiles of proteins modified by the main ubiquitin family members. Indeed, we have successfully applied this protocol to generate profiles of PTMs by ubiquitin, and also by SUMO and Nedd8, and to detect alterations associated with a treatment7, in response to the over expression or knockdown of a certain gene (data not shown) and in cells that acquired a resistant phenotype to diverse chemotherapeutic drugs.

Ujawnienia

The authors have nothing to disclose.

Podziękowania

This work was supported by La Ligue Contre le Cancer to HV and MS, and the ARC (association pour la recherche sur le cancer) to PS, INCa (institute national du cancer) and Canceropole PACA to JI. The mass spectrometry facility of Marseille Proteomics (marseille-proteomique.univ-amu.fr) supported by IBISA (Infrastructures Biologie Santé et Agronomie), Plateforme Technologique Aix-Marseille, the Cancéropôle PACA, the Provence-Alpes-Côte d'Azur Région, the Institut Paoli-Calmettes and the Centre de Recherche en Cancérologie de Marseille.

Materiały

NameCompanyCatalog NumberComments
ANTI-FLAG M2 Affinity GelSigma-AldrichA2220-5MLbinds all Flag tagged proteins
anti-Flag M2 antibodySigma-AldrichF3165to detect 6His-Flag tagged expression of ub/ubl
Cell strainer 40 µmFalcon352350to remove floating pellet from guanidine lysed cells
Flag peptideSigma-AldrichF3290elute flag tagged proteins from anti-flag beads
Guanidine hydrochlorideSigma-Aldrich50933chaotropic agent used to denature all proteins in cell lysate
ImidazoleSigma-AldrichI5513eluates 6His bond proteins from Ni-NTA beads
Lipofectamine 3000ThermoFisherL3000015to transfect HEK-293T cells to produce lentiviruses
Lobind tubesSigma-AldrichZ666491avoids absorption of precious material
Membrane Filter, 0.45 µmMilliporeHAWP04700F1to filter the lentiviral supernantant
Ni-NTAQiagen30210purification of the 6His tag

Odniesienia

  1. Prabakaran, S., Lippens, G., Steen, H., Gunawardena, J. Post-translational modification: Nature's escape from genetic imprisonment and the basis for dynamic information encoding. Wiley Interdisciplinary Reviews: Systems Biology and Medicine. , (2012).
  2. Hochstrasser, M. Origin and function of ubiquitin-like proteins. Nature. 458 (7237), 422-429 (2009).
  3. Kirkpatrick, D. S., Weldon, S. F., Tsaprailis, G., Liebler, D. C., Gandolfi, A. J. Proteomic identification of ubiquitinated proteins from human cells expressing His-tagged ubiquitin. Proteomics. 5 (8), 2104-2111 (2005).
  4. Peng, J., et al. A proteomics approach to understanding protein ubiquitination. Nature Biotechnology. 21 (8), 921-926 (2003).
  5. Matsumoto, M., et al. Large-scale analysis of the human ubiquitin-related proteome. Proteomics. 5 (16), 4145-4151 (2005).
  6. Hjerpe, R., Rodríguez, M. S. Efficient approaches for characterizing ubiquitinated proteins. Biochemical Society Transactions. 36 (5), 823-827 (2008).
  7. Bonacci, T., et al. Identification of new mechanisms of cellular response to chemotherapy by tracking changes in post-translational modifications by ubiquitin and ubiquitin-like proteins. Journal of Proteome Research. 13 (5), 2478-2494 (2014).
  8. Bedford, L., Lowe, J., Dick, L. R., Mayer, R. J., Brownell, J. E. Ubiquitin-like protein conjugation and the ubiquitin-proteasome system as drug targets. Nature Reviews Drug Discovery. 10 (1), 29-46 (2011).
  9. Hoeller, D., Dikic, I. Targeting the ubiquitin system in cancer therapy. Nature. 458 (7237), 438-444 (2009).
  10. Silva, J. C., Gorenstein, M. V., Li, G. Z. Z., Vissers, J. P. C., Geromanos, S. J. Absolute quantification of proteins by LCMSE: a virtue of parallel MS acquisition. Molecular & Cellular Proteomics. , (2006).
  11. Kim, W., et al. Systematic and quantitative assessment of the ubiquitin-modified proteome. Molecular Cell. 44 (2), 325-340 (2011).

Przedruki i uprawnienia

Zapytaj o uprawnienia na użycie tekstu lub obrazów z tego artykułu JoVE

Zapytaj o uprawnienia

Przeglądaj więcej artyków

UbiquitinPost translational ModificationsLentivirusesStable Cell LinePurificationDisease AlterationsPrognostic MarkersEukaryotic ModelHEK 293T CellsTransfectionLentivirus ProductionPurification ProtocolTransduction

This article has been published

Video Coming Soon

JoVE Logo

Prywatność

Warunki Korzystania

Zasady

Badania

Edukacja

O JoVE

Copyright © 2025 MyJoVE Corporation. Wszelkie prawa zastrzeżone